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Abstract
Pharmaceutical patents are categorized into primary 
patents and secondary patents. Primary patents refer 
to compound patents, while secondary patents mainly 
include crystalline form patents, process patent, 
formulation patent and method of use patent. In the recent 
outbreak of COVID-19, Wuhan Institute of Virology, has 
applied for a new method of use patent on Remdesivir for 
its efficacy and safety in the treatment of the pneumonia 
caused by 2019-nCoV. But Gilead Sciences, the inventor 
of Remdesivir, is the eligible holder of the compound 
patent of Remdesivir. In theory, the patent applied for by 
Wuhan Institute of Virology has utility and novelty rather 
than innovativeness, for which it may not be granted 
the method of use patent of Remdesivir. In this case, we 
suggest that the patent of Remdesivir be implemented 
through cross licensing and compulsory licensing between 
different patent holders. 
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The epidemic of the novel coronavirus 2019-nCoV 
detected in Wuhan, a central city of China, has spread 
around the country since the very beginning of 2020. At 
this critical moment, China’s president Xi Jinping stressed 
the utmost importance of carrying out prevention and 
control measures in a science-based, legal and orderly 
manner at the third meeting of the Commission for 
Overall Law-based Governance of the CPC Central 
Committee. Amid the combat against the epidemic, a 
debate has arisen over the application by Wuhan Institute 
of Virology, Chinese Academy of Sciences for a patent on 
the utility of Remdesivir, a possible cure for COVID-19. 
Certainly, how the debate is to be settled will influences 
the way prevention and control is conducted and how 
patients are treated in China. Thus, an in-depth analysis 
of Remdesivir patenting will shed light on the discussion 
of its method of use patent and furthermore help combat 
against the virus. 
1 .  TYPES OF  PHARMACEUTICAL 
PATENTS
The application filed by Wuhan Institute of Virology, 
as alleged, is for a patent on a new treatment method 
of Remdesivir. Patents on method of use belong to 
pharmaceutical patents. And compound patents, like 
the one Gilead Sciences obtained for its Remdesivir 
(CN103052631B) in China,  represents the most 
important category in pharmaceutical patents for the 
fundamental role that compounds play in the invention 
of drugs. Furthermore, compound patents have various 
sub-categories including patents on basic compounds, 
prodrugs, pharmaceutically acceptable salts and active 
metabolites, etc. In fact, different types of patents can be 
applied for with different pharmaceuticals. For instance, 
a pharmaceutical company can apply for two drug patents 
respectively on drug A and drug B, and it is also the case 
for drug A and its active metabolites. If a newly invented 
drug has been granted the compound patent its inventor 
can become the monopoly seller of the drug. 
Generally, a pharmaceutical patent is aimed to protect 
the products, formulation and uses that the patent holder 
invents. (Xiao, 2012) Compound patents are primary 
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patents, while the various patents derived from a patented 
compound are called secondary patents, which include 
crystalline form patents, process patents, formulation 
patents and method of use patents. 
Figure 1
Types of pharmaceutical patents
A crystalline form patent is a patent on one of the 
different crystalline forms of a drug substance. For 
drugs with an identical chemical structure, different 
crystals can be obtained in different crystallization 
conditions. Improved crystalline forms will enhance 
the performance of a drug in quality and efficacy by 
optimizing its active ingredients, preparation stability, 
solubility and bioavailability. Crystalline forms, like 
those of Remdesivir patented in China, are common 
in pharmaceutical research and development and 
protection. In practice, crystalline forms of drugs 
that can be patented and protected include but are not 
limited to single crystals, polymorphs, cocrystals, 
crystalline hydrates, solvates, amorphous solids, 
crystalline forms of different particle sizes, etc. (Huang, 
Qian, et al, 2017) Yet so far, many problems in terms 
of the protection of pharmaceutical crystalline forms 
still remain unaddressed, among which the most 
prominent is the absence of a set of universal standards 
in the examination of the novelty of pharmaceutical 
crystalline forms. (Zhang, Ma, etc., 2016)
A process patent claims the process used to 
create or manufacture a drug. In many cases, there 
are more than one way to produce a drug. Gilead 
Sciences, for example, can apply for another process 
patent after it successfully achieves optimization 
i n  t h e  m a n u f a c t u r i n g  p r o c e s s  o f  R e m d e s i v i r 
(CN107074902A) that  i t  f irst  invented,  such as 
simplif ied manufacturing techniques,  increased 
productivity and better performance in environmental 
protection.
A formulation patent claims the pharmaceutical 
dosage form of a drug, which means different dosage 
forms of a drug might be granted different formulation 
patents. Gilead Sciences, again, can apply for another 
formulation patent with its newly invented sustained-
release Remdesivir tablets though it has obtained one for 
its earlier Remdesivir tablets. 
A method of use patent claims the “use of drug A 
to manufacture a pharmaceutical dosage form to treat 
disease B.” Examples are sildenafil, which was first a 
medication used to treat cardiovascular diseases before 
it was discovered to be effective for treating erectile 
dysfunction, and Remdesivir, which was originally 
invented for treating coronaviruses MERS and SARS and 
may possibly be used to treat COVID-19. 
The four types of patents above are applied for at 
different points along the timeline of drug research and 
development. A proven inventor drug will always lead to 
the improvement of its manufacturing technique for lower 
costs, and the inventor will apply for a process patent 
on the technique to prevent potential infringement. An 
optimized dosage form or crystalline form of a drug based 
on clinical efficacy or in response to the clinical demands 
of other patients and the business strategy to expand 
market shares can also help the inventor to acquire a 
formulation patent and a crystalline form patent. If a new 
method of use is discovered after the drug goes into the 
market, the company can also apply for a method of use 
patent for it. 
Figure 2
Patent cluster in the timeline of drug research and 
development
Method of use patents and medical diagnosis and 
treatment methods. According to China’s Guidelines for 
Patent Examination, a patent shall not be granted for 
a substance for use in medical diagnosis and treatment 
but for use in drug manufacturing. In other words, the 
invention of a substance for medicinal use is patented 
on the basis of a product claim or a manufacture method 
of use claim, such as “applications in pharmaceuticals” 
or “applications in the preparation of a drug for the 
treatment of a disease.” Accordingly, for method of use 
patent application in China, “substance A for use in the 
manufacture of the drug for disease B” must be clearly 
stated in claims instead of “substance A for use in the 
treatment of disease B.”
Method of use patent application is much more 
common in pharmaceutical chemistry than in other areas. 
For one thing, a change in a compositional element or 
a molecule structure may possibly result in a difference 
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in efficacy. In most cases, what effect a drug has when 
it is with a specific structure (or a family of structures) 
or a specific chemical formula (or a family of chemical 
formula) still remains unknown. Further efforts in in 
vitro cell experiments, animal experiments and clinical 
trials, therefore, are required to get closer to the exact 
efficacy a drug can deliver. So far, more than ten 
thousand kinds of diseases have been disclosed to the 
human world, with more being revealed continuously. 
The fact is, it would be impossible for humans to learn 
all the details of every disease, so the existence of an 
unknown use of a known drug is common. For another, 
it normally takes about twelve years and a huge amount 
of investment for a pharmaceutical company to go 
through the lengthy process from laboratory research 
to establishment in the market when it comes to the 
invention of a new drug. That’s why pharmaceutical 
companies prefer to invest instead in a new use of a 
patented drug. 
2 .  M E T H O D  O F  U S E  P A T E N T 
APPLICATION OF REMDESIVIR
Remdesivir, an antiviral drug invented by Gilead 
Sciences, an American pharmaceutical company, 
was originally used for Ebola virus infection before 
it was discovered to have antivirus activity against 
Severe Acute Respiratory Syndrome Coronavirus 
(SARS-CoV) and Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV). 
Amid the current epidemic, China’s Wuhan Institute 
of Virology has discovered in its study that Remdesivir 
showed effects in suppressing the coronavirus, so on 
January 21st, 2020, the Institute filed its application for a 
patent on the new use of Remdesivir. This has since led 
to a heated debate among the public. Supporters believe 
that the Institute set a good example for the public by 
displaying a strong sense of intellectual property in its 
efforts to have its discovered use patented regardless 
of the result of patent examination. Meanwhile, the 
application is not an attempt for a bad-faith infringement 
of the patent acquired by Gilead, as the application was 
submitted on January 21st, 2020, ten days before the paper 
titled Brief Report: First Case of 2019 Novel Coronavirus 
in the United States was published. Thus, the new 
method of use invented by Wuhan Institute of Virology 
should be granted a method of use patent for its novelty 
and innovativeness as required in the Patent Law of the 
People’s Republic of China. Furthermore, it is legitimate 
for the Institute to protect the interests of its country. 
What it is trying to do is to break up the monopoly of 
Remdesivir in the Chinese market, which it’s started with 
a secondary patent of the drug. If successfully granted, the 
patent would be a bargaining chip in its cooperation with 
Gilead in research and development and in future cross-
licensing negotiations with pharmaceutical companies 
from other countries. (Liu, 2020)
On the contrary, dissenters argue that a simple 
trial with the published data from Gilead is sheer 
plagiarism. It lacks the “novelty and innovativeness” 
that an invention features and therefore should not be 
given a patent. They contend that the Institute is trying 
to safeguard its own interests rather than national 
interests, which may involve academic assessment and 
titles for researchers and patent application targets 
and material rewards for the Institute. If true, it comes 
completely against the purpose of patent legislation. 
Additionally, domestic pharmaceutical companies 
manufacturing and selling the Remdesivir for the 
treatment of the new coronavirus will have to obtain 
dual authorizations from both Gilead Sciences and 
Wuhan Institute of Virology if the patent is eventually 
granted. As to whether the new method of use will be 
made widely accessible without costs, that’s unable to 
find out yet. (Xiong, 2020)
Both sides have their  focus in this  problem. 
Supporters believe, firstly, that the patent application 
by the Institute is a reasonable move, for the new use 
of Remdesivir it discovered in displaying suppressive 
activity against the virus demanded tremendous efforts 
in experiments with creativity. The inventor therefore 
has the right to apply for a patent for legal protection 
and it is not a bad-faith intent. But whether the patent 
will be granted depends on multiple factors. 
Secondly, the patent that the Institute applied 
for is different from the ones Gilead had applied 
in China. According to our patent search, Gilead 
has legally acquired the patent on the compound of 
Remdesivir (CN103052631B) and the patent on the 
halogenated compound that is similarly structured 
with Remdesivir in China. Later in 2016 and 2018, the 
American company further applied respectively for the 
patent on the treatment of arenavirus and coronavirus 
infections and the patent on the polymorph and 
maleate form of the compound of Remdesivir, which 
are still under examination in China. As known, the 
compound patent acquired by Gilead is a primary 
patent while the method of use patent applied for by 
Wuhan Institute of Virology falls into the category 
of secondary patents. That means the two do not 
overlap at all. In practice, the compound patent of 
Remdesivir Gilead has obtained will remain effective 
and legitimate even if the application by Wuhan 
Institute of Virology later proves valid. Conversely, the 
examination of this method of use will be subject to 
the verdict that China’s authority returns with regard 
to Gilead’s application for the patent on the treatment 
of coronavirus infections. 
Opponents, however, contend that the method of use 
patent applied for by the Institute should be not granted, 
for the innovativeness required for an invention is absent. 
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According to Article 22 of the Patent Law of China, 
“inventions and utility models for which patent rights are 
to be granted shall be ones which are novel, innovative 
and of practical use.” 
As far as the authors are concerned, the new 
method of use discovered by Wuhan Institute of 
Virology does have practical use. As learned from the 
Patent Law of China, “practical use means that the said 
invention or utility model can be used for production 
or be utilized, and may produce positive results.” With 
the epidemic, researchers in the Institute detected the 
remarkable effect Remdesivir scored in dealing with 
pneumonia brought by 2019-nCoV from a large pool 
of candidates, which proves to have “practical use” as 
defined above.
In addition to practical use, this new method of use 
is also of novelty. Chronologically, the Institute filed its 
application on January 21st, 2020, ten days earlier than 
when the data about the antivirus activity that Remdesivir 
shows against the virus was published. 
According to the public information from the National 
Genomics Data Center (NGDC), the overall sequence 
of the virus shares an 80.12% resemblance with that of 
SARS-CoV. That’s why its RDRP shows a significant 
difference from RDRP in the coronavirus family. The 
domain of Remdesivir works as competitor to inhibit 
RDRP. As a key enzyme for RNA virus replication, 
RDRP causes a decrease in viral reproduction by 
suppressing the activity of the virus. Therefore, the new 
use of Remdesivir (anti-2019-nCoV) cannot be directly 
revealed with the mechanism and pharmacological 
effects of the previously known uses against other 
members of the coronavirus family. Moreover, the new 
use differentiates more than just in the dosage, time, and 
frequency in the drug delivery. All these combined to 
suggest that the new use is substantially different from 
the previously known ones and it is an addition to the 
known uses of Remdesivir.
As China’s Guidelines for Patent Examination 
suggests, the disclosure of general (high-level) concepts 
is not prejudicial to inventions defined by specific (lower-
level) concepts. For instance, the difference between 
a claimed invention and a reference document is that 
“halogen” or another specific halogen “fluorine” in 
the reference document is replaced by “chlorine” in 
the invention claim, so the disclosure of “halogen” or 
“fluorine” in the reference document is considered as 
non-prejudicial to the invention defined by “chlorine”. 
Accordingly, despite the fact that Gilead Sciences applied 
for a patent for coronavirus infections treatment, the new 
use patent of anti-2019-nCoV Wuhan Institute of Virology 
applied for is a prejudicial disclosure to that of anti-
coronaviruses, as 2019-nCoV belongs to the coronavirus 
family, a higher-level concept. 
Finally,  the patent for the use of Remdesivir 
from Wuhan Institute of Virology is not considered 
innovative. According to the Guidelines for Patent 
Examination ,  a  new use of  a  known product  is 
considered to be innovative when it is derived or can 
be predicted obviously from the structure, composition, 
molecular weight, known physicochemical properties 
and the current uses of the product and is used to 
produce unpredictable technical effects with the 
newly discovered properties of the product. Thus, 
the innovativeness of an invention is the key to the 
“obviousness” and “unpredictable technical effects” 
that a new use features. It is also pointed out in the 
Guidelines for Patent Examination that to determine 
whether the claimed invention is “obvious” to the prior 
art, the following three steps need to be performed: 
de te rmine  the  c loses t  p r ior  a r t ;  de te rmine  the 
distinctive features of the invention and the technical 
problems that the invention solves; and determine 
whether the claimed invention is obvious to those 
skilled in the art. As for “unpredictable technical 
effects”, it requires more than just differences or 
changes to previous technical effects. The most critical 
and indispensable requirement is “unpredictability”, 
which needs to be evidenced by experimental data. 
(Zhang, 2012)
Gilead Sciences applied for  a  patent  for  the 
treatment of arenavirus and coronavirus infections 
(CN108348526A) in China in 2016 and made it public 
on July 31, 2018. Relevant vitro cell experiments 
and animal model experiments both proved that 
Remdesivir has antiviral effects on SARS-CoV and 
MERS-CoV (Table 3 and Table 4). In a paper from 
Wuhan Institute of Virology that was published on 
Cell Research, it says “studies show that in VeroE6 
cells, EC50 of Remdesivir (GS-5734) is 0.77μM and 
its SI is greater than 129, while EC50 of Chloroquine 
is  1.13 uM and i ts  SI is  greater than 88. These 
numbers indicate that  the two drugs above can 
effectively inhibit COVID-19 infections at the cellular 
level, but their effects on the human body still need to 
be clinically verified” (Figure 5).
Table 3
In Vitro Experimental Data of Remdesivir (compound 
32) Directed against MERS Disclosed in Gilead 
Sciences’ Patent Application1
EC50 (μM)
Determination
Virus MERS-CoV
Cell Line Vero
Compound 9 0.46
Compound 32 0.58
1The treatment of arenavirus and coronavirus infections. http://epub.
sipo.gov.cn/patentoutline.action. Feburary 20th, 2020.
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Table 4
Antiviral activity and cytotoxicity of compound 1 and 
compound 32 against MERS-CoV and SARS-CoV 2
0
EC50 (μM)1
CC50 (μM)
MERS SARS
Compound 
1
0.46 (HAE)
--(Calu-3)
0.22 (HAE)
--(Calu-3)
>100 (HAE)
>100 (Calu-3)
Compound 
32
0.074 (HAE)
0.03 (Calu-3)
0.069 (HAE)
0.01 (Calu-3)
>10 (HAE)
>10 (Calu-3)
All the data are the average of more than 3 independent 
experiments. HAE=Human Airway Epithelial Cells. Calu-
3=A human lung cancer line cell Calu-3 (Calu3-2B4). 
HAE research was accomplished by three donors.
In vitro experimental data of remdesivir (compound 
32) directed against MERS and SRAR disclosed in gilead 
sciences’ patent application.
Figure 1
In vitro experimental data of remdesivir in vero E6 
cells in the paper by Wuhan institute of virology (Wang, 
Cao, Zhang, et al., 2020) 
COVID-19  i s  a  member  o f  the  coronav i rus 
family, though it shares a mere 80.12% sequence 
identity with SARS-CoV. Based on the structure, 
c o m p o s i t i o n ,  m o l e c u l a r  w e i g h t ,  a n d  k n o w n 
physicochemical properties of Remdesivir, together 
with its experimental designs and valid data in SARS-
CoV and MERS-CoV (both have been published), 
the idea that Remdesivir has a therapeutic effect for 
treating COVID-19 can be accordingly confirmed. 
This  l eads  technica l  personne l  in  the  f ie ld  o f 
biomedicine to perform relevant experiments on the 
drug. Table 3 and Figure 1 show that the control 
group in the experimental design of Wuhan Institute 
of Virology has previously emerged in the in vitro 
cell  experiments of Remdesivir directed against 
coronaviruses, which suggests a remarkable similarity 
between these two experimental designs. As far as the 
authors are concerned, this case is in line with what 
the Guidelines for Patent Examination stipulates, 
“what needs to be determined is whether there is some 
technical revelation in the prior art as a whole. That 
2The treatment of arenavirus and coronavirus infections. http://epub.
sipo.gov.cn/patentoutline.action. Feburary 20th, 2020.
is to say, to determine whether the prior art reveals 
such distinguishing features mentioned above that can 
be applied to the closest prior art to solve its existing 
technical  problems,  which means the technical 
problems can be solved by the invention. This kind 
of revelation will motivate those skilled in the art to 
improve the closest prior art and obtain the claimed 
invention when they are facing the technical problem. 
If such technical revelation exists in the prior art, 
the invention to be claimed is considered as obvious 
and does not have outstanding substantive features.” 
Therefore, the invention claimed by Wuhan Institute 
of Virology is obvious.
As shown in the results of the in vitro cell experiments, 
Remdesivir has a comparable antiviral effect on 
COVID-19 and MERS. (Table 6) (As the cells used in the 
in vitro cell experiments of Remdesivir against SARS-
CoV are different from those for the novel coronavirus, 
comparison will not be made here.) However, the antiviral 
effects of Remdesivir on COVID-19 and MERS are 
consistent, and there was no discovery of new physical or 
chemical properties of Remdesivir. Except for the viruses, 
other experimental data, including mechanism and 
physical properties of Remdesivir, are mostly the same as 
those from Gilead Sciences. Thus, the process and results 
of the experiments presented in the experimental data 
from Wuhan Institute of Virology are predictable. 
Table 6
Comparison of antiviral activity of remdesivir between 
novel coronavirus and MERS
Remdesivir EC50 (μM)
2019-nCoV 0.77
MERS 0.58
To summarize, the invention filed by Wuhan Institute 
of Virology is apparently “obvious” and does not produce 
“unpredictable technical effects” and thus is deemed to 
be non-innovative according to the Guidelines for Patent 
Examination. That means it may not be patented as an 
invention against the novel coronavirus. 
3 .  T H E  I M P L E M E N T A T I O N  O F 
REMDESIVIR PATENTS
Remdesivir patents, either compound patents or method 
of use patents, carry their values in implementation. In the 
combat against the 2019-nCoV, compulsory licensing and 
cross licensing may both be used in the implementation of 
Remdesivir patents. 
3.1 Compulsory Licensing
In the Patent Law of China, Article 49 says “where 
a national emergency or any extraordinary state of 
affairs occurs, or public interests so require, the patent 
administration department under the State Council may 
grant a compulsory license for exploitation of an invention 
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patent or utility model patent.” Accordingly, the following 
conditions must be satisfied if compulsory licenses are to 
be used. 
Firstly, the patents, either compound patents or method 
of use patents, must be granted by China’s authority. 
Otherwise, inventions will not be subject to compulsory 
licensing if not patented like the one on the treatment 
of arenavirus and coronavirus infections or the other on 
the polymorph and maleate form of the compound of 
Remdesivir. 
Secondly, compulsory licenses can only be granted 
and used in a national emergency and extraordinary 
situation to protect the public’s interests. If, under 
extreme circumstances, the patentee opposes the 
compulsory license in defiance of public health, 
national authorities have the right to restrict the 
legal rights of the patent holder (Hu & Xu, 2005) by 
compulsory licensing. 
Lastly, compulsory licenses shall be granted by 
China’s National Intellectual Property Administration, 
the patent administration department under the State 
Council, rather than that of the municipal government 
of Wuhan or the provincial government of Hubei. 
With these three conditions satisfied, it will still 
depend largely on actual situations as to whether 
the National Intellectual Property Administration 
will grant a compulsory patent or not. The inventor 
of Remdesivir, Gilead Sciences, has made a clear 
announcement that all Remdesivir provided for clinical 
trials in China would be free of charge. Thus, no 
compulsory licenses are needed in this case. 
3.2 Cross licensing
In  the  case  where  a  new use of  an es tabl ished 
drug is patented while the product patent of the 
drug belongs to another party, a cross-licensing 
agreement is required in the implementation of this 
patent. “Cross licensing is a licensing method where 
patentees exchange licenses so that they can access 
the invention of the other party.” (Liu, 2014) It is 
believed that if the patent application by Wuhan 
Institute of Virology is approved, the Institute can 
reach a cross-licensing agreement with Gilead on the 
compound patent (CN103052631B) and the method 
of use patents of Remdesivir. From the authors’ point 
of view, this cross-licensing is theoretically possible. 
For one thing, whether the patent applied for by the 
Institute will eventually granted still remains pending. 
For another, Gilead may not have to obtain the license 
from the Institute even if it is granted. As the 2019-
nCoV is a member of coronaviruses, it is possible 
that superindication medication, also called off-label 
drug use, exists in clinical treatment. (Yao, 2012) In 
this case, Gilead does not need a cross license from 
the Institute. Normally, a drug information leaflet 
is  composed based on the content in the patent 
specification of the drug. In its patent specification, 
Remdesivir’s efficacy description should be “used to 
treat infections caused by coronaviruses” instead of 
“used to treat 2019-nCoV infections.” With Remdesivir 
effective in treating the novel coronavirus, physicians 
can exercise their right to prescribe Remdesivir in 
confirmed cases without the authorization from Wuhan 
Institute of Virology. Meanwhile, superindication 
medication does not make a medical infringement 
unless there is medical malpractice in the process. 
Therefore, it does not matter whether Gilead is given a 
license from the Institute even if the patent application 
for the new use against 2019-nCoV is approved. 
Still ,  more questions are raised: can Gilead’s 
patents on Remdesivir be implemented in China 
fo r  the  t r ea tmen t  o f  COVID-19?  Can  China ’s 
National Intellectual Property Administration grant 
a compulsory license? If yes, is it an infringement of 
Gilead’s patent? Our answer is intellectual property 
right is a regional or national concept, which means 
“intellectual property rights acquired in accordance 
with the laws of a country are valid only in that 
country and carry no legal effect in other countries.” 
(Wu, 2003) Accordingly, the patent rights of Remdesivir 
granted by US authorities will be only protected by US 
Patent Law and carry no legal effect in China as it is not 
patented in the country. So, inventors should have their 
inventions patented in accordance with the international 
intellectual property treaties, bilateral agreements, 
multilateral agreements or the principle of reciprocity and 
the patent laws of some certain countries or regions if they 
desire to obtain patent law protection for their inventions 
there. Furthermore, if a pharmaceutical company produces 
and sells Remdesivir during the epidemic in China, 
the behavior of the pharmaceutical company is not an 
infringement of patent rights even without the permission 
of Gilead, as the American company does not enjoy 
patent rights in China. It is possible that the move of 
the pharmaceutical company falls into the area of unfair 
competition and will be regulated according to China’s 
Anti-Unfair Competition Law. Last but not least, a drug 
patent is the prerequisite for drug compulsory licensing, 
so it is impossible to grant a compulsory license for a 
patent on a drug invention that has not been applied for 
(obtained) in China. 
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